tumor perivascular niche-the primary location of GBM stem cell-like (GSC) populations . GSCs have stem cell-like properties and are thought to highly contribute to the cellular heterogeneity of GBM (Lathia, Mack, Mulkearns-Hubert, Valentim, & Rich, 2015) . The perivascular niche is also composed of several stromal cells including microglia, astrocytes, pericytes, fibroblasts, and endothelial cells that support tumor progression (Zhao et al., 2017) . Furthermore, these tumors are also characterized by their ability to interact with the extracellular matrix (ECM) of the brain to favor their survival (Herrera-Perez, Voytik-Harbin, & Rickus, 2015; Nakod, Kim, & Rao, 2018) . The brain ECM occupies a significant proportion of the CNS and contributes to its normal physiology (Lau, Cua, Keough, HaylockJacobs, & Yong, 2013) . Most of the components of the brain ECMnamely, hyaluronic acid, proteoglycans, and associated proteins-are overexpressed by tumor and tumor associated cells during GBM development. Therefore, typical ECM proteins such as fibronectin have been directly linked to tumor invasion by their ability to regulate cell adhesion and migration (Chen, Lee, Radisky, & Nelson, 2013) .
Besides, accumulating evidences suggest that hyaluronic acid plays a crucial role during GBM invasion in the healthy brain (Misra, Hascall, Markwald, & Ghatak, 2015) .
The growth of solid tumors including GBM is highly dependent on neo-angiogenesis through which new blood vessels arise from preexisting vessels (Vasudev & Reynolds, 2014) . During this process, tumor cells secrete proangiogenic factors such as vascular endothelial factor-A (VEGF-A) that can affect surrounding endothelial cells in order to promote their proliferation and rearrangement into blood vessels that consequently integrate into the tumor (Dey, Ulasov, & Lesniak, 2010) . This way, a constant supply of oxygen and nutrients is established to counteract hypoxia at the tumor core. Consequently, the use of anti-angiogenic drugs such as bevacizumab that neutralizes VEGF-A has been extensively studied the last two decades to decrease tumor growth (Chinot et al., 2014; Gilbert et al., 2014) .
Nevertheless, these therapies are still of very limited benefits while some of their effects are controversial (Simon et al., 2014; Simon, Gagliano, & Giamas, 2017) . In addition to their central role in neo-angiogenesis, endothelial cells have been shown to secrete mediators such as transforming growth factor-β (TGF-β) (Anido et al., 2010) , b-FGF (Fessler, Borovski, & Medema, 2015) , and epidermal growth factor (EGF) (Schulte et al., 2012) that promote the maintenance of the GSCs self-renewing properties in culture .
Tumor-associated microglia are also observed within the GBM microenvironment (Mildner et al., 2007; Quail & Joyce, 2017) . For instance, microglia cells have been reported to promote glioma invasiveness in vitro through the action of the matrix metalloproteases, MMP2 and MMP9 Markovic, Glass, Synowitz, van Rooijen, & Kettenmann, 2005) . In a well-defined mechanism, tumor associated microglial cells secrete TGF-β that promotes the GBM cells' release of pro-MMP2 and versican. In response to versican, the tolllike receptor 2 (TLR2) on tumor associated microglia is activated and consequently induces the activation of the p38-MAPK pathway leading to the expression of membrane-type 1 matrix metalloprotease (MT1-MMP). This is followed by the cleavage and activation of pro-MMP2 by MT1-MMP. Ultimately, MMP2 then degrades ECM components such as gelatins, collagen, and elastins, enhancing GBM cell invasion (Charles et al., 2011) .
The role of the endothelial cells (i.e., neo-angiogenesis) and immune/microglia cells during GBM development has already been intensively reported and is now well deciphered. Regarding astrocytes, despite being the most abundant glial cells in the CNS and therefore highly abundant within the GBM microenvironment, their impact on the tumor development is yet to be fully understood (Jakel & Dimou, 2017; O'Brien et al., 2013) . Nevertheless, a few recent reports have acknowledged that question so that the interest about the role of astrocytes on the GBM microenvironment is constantly increasing (Oushy et al., 2018; Quail & Joyce, 2017) .
Indeed, as a correlation between astrocyte subpopulations and GBM subtypes has been noticed, signaling pathways through which astrocytes are able to influence GBM cell invasion, resistance, and interactions with their direct cell counterparts have also been thoroughly investigated.
| ROLES OF ASTROCYTES IN THE HEALTHY CENTRAL NERVOUS SYSTEM AND PATHOLOGY

| Astrocytes at the brain-blood barrier
Astrocytes are the "star-shaped" cells of the CNS known to play active and dynamic roles in the healthy and diseased brain (Davila, Thibault, Fiacco, & Agulhon, 2013; Reemst, Noctor, Lucassen, & Hol, 2016) . For example, astrocytes are directly implicated in the structure and tightness of the brain-blood barrier (BBB). The BBB lines the cerebral microvasculature that provides the brain with oxygen and nutrients.
Forming the main BBB structure, the end-feet of astrocytes closely associates with the outer surface of the vasculature (Zhao, Nelson, Betsholtz, & Zlokovic, 2015) . Through tight junctions, astrocytes directly interact with both endothelial cells and pericytes, thus supporting BBB maintenance and dynamic (Alvarez et al., 2011; Horng et al., 2017) .
| Astrocytes modulate synaptic activity and plasticity
Normal brain function is dependent on a balance between inhibitory and excitatory transmission (Farhy-Tselnicker & Allen, 2018) .
Astrocytes play a central role in regulating this balance as they are able to rapidly and efficiently remove neurotransmitters from the synaptic cleft (Belanger & Magistretti, 2009) . Astrocytic processes found in association with excitatory synapses are rich in glutamate transporters such as glutamate aspartate transporter (GLAST) and glutamate transporter 1 (GLT-1) allowing them to maintain the low physiological concentrations of the excitatory neurotransmitter glutamate, thereby limiting neuronal excitation (Chung, Allen, & Eroglu, 2015) . In addition, astrocytes activity modulates volume transmission, a process during which neurotransmitters diffuse across the brain extracellular space via astrocytes to activate extrasynaptic receptors (Vargova & Sykova, 2014) .
| Astrogliosis
In addition to the roles astrocytes play in the healthy CNS, they are also responsive to CNS damage and are subject to astrogliosis, a process whereby astrocytes undergo a number of molecular, cellular, and functional changes to form reactive astrocytes able to repair the affected tissue (Sofroniew, 2014) . During astrogliosis, reactive astrocytes become hypertrophic and they can proliferate and increase in number at the lesion site (Sofroniew, 2009) . Also, according to recent publications, the main component of astrocyte intermediate filaments, namely, the glial fibrillary acidic protein (GFAP), is found to be upregulated in reactive astrocytes, along with Nestin and Vimentin, transcription factors (e.g., STAT-3), signaling receptors (e.g., c-MET), growth factors (e.g., brain derived neurotrophic factor (BDNF), growth/differentiation factor 15 (GDF-15)), inflammatory cytokines (e.g., C-C motif chemokine ligand 2 (CCL2), interleukin 6 (IL-6)), extracellular matrix components (e.g., collagens, versican) and cell adhesion proteins (e.g., CD44), all in the aim to support tissue repair (Boccazzi & Ceruti, 2016) . Among them, some might be considered as potential specific markers of reactive astrocytes (e.g., GFAP) (Zamanian et al., 2012) . Therefore, GFAP labeling shows that reactive astrocytes seem to form a border between CNS lesions (e.g., experimental autoimmune encephalitis) and the surrounding tissue (Voskuhl et al., 2009) . This lesion "sequestration" may play a role in speeding up clinical stabilization and thereby improving patients' survival (Cregg et al., 2014) . Similarly, reactive astrocytes have also been shown to be involved in facilitating BBB repair (Sofroniew, 2009) .
| ROLE OF ASTROCYTES DURING GLIOBLASTOMA DEVELOPMENT
As tumor development involves healthy tissue invasion and subsequent destruction, astrogliosis can also occur in response to GBM growth (O'Brien et al., 2013) . Thus, it has been shown through bioluminescence that astrogliosis peaks 3 days postimplantation of tumor cell lines in mice (Lee, Borboa, Baird, & Eliceiri, 2011) . Nevertheless, even though this process initially aims to aid repairing the healthy brain tissue and fight the progression of the tumor, the same mechanisms might as well support tumor growth under the influence of GBM cells (O'Brien et al., 2013) . Interestingly, the nuclear factor kappa-B (Nf-κB)-dependent signaling might be involved in the activation of astrocytes into tumor-associated astrocytes (TAAs) upon GBM growth (Kim et al., 2014b) . Indeed, receptor activator of Nf-κB ligand (RANKL) has been reported to be produced by GBM cells, so it can reach its receptor RANK at the astrocytes' surface to activate them through the Nf-κB pathway, leading to the rising of TAAs. Those TAAs then produce tumorpromoting factors such as TGF-β enhancing GBM cell invasion (Kim, Jin, et al., 2014b) . In the same way, Priego et al. (2018)) recently showed that STAT-3 might drive a protumoral program activation in reactive astrocytes in an in vivo model of brain metastasis.
| Significance of different astrocytes subpopulations in the GBM microenvironment
Astrocytes from different CNS regions present vastly distinct morphological, molecular, and functional properties, suggesting the existence of heterogeneous subpopulations (Farmer & Murai, 2017) . Consequently, TAAs found in the GBM microenvironment might express specific markers that differentiate them from normal astrocytes.
Indeed, through establishing the mRNA profile of TAAs in an in vivo PDGF-driven model of GBM (proneural GBM subtype), Katz et al. have been able to identify genes from the antigen presentation pathway but also CD44 and tenascin-C that are potentially overexpressed by GBM-associated astrocytes exclusively. Consequently, these data suggest very specific roles for TAAs in the GBM interactions with its surrounding microenvironment (Katz et al., 2012) . In the same report, authors observed two distinct populations of TAAs in the same tumor bulk with TAAs at the tumor periphery being slightly different to those in the tumor perivascular niche. They noticed that TAAs surrounding the tumor seems similar to "normal" reactive astrocytes (swollen cell bodies and hyperextended processes) while the CD44 and tenascin-c overexpression was mostly restricted to the perivascular TAAs (Katz et al., 2012) . In accordance to this observation, Lin et al. reported the correlation between specific astrocyte subpopulations and GBM progression. In this study, intersectional fluorescence-activated cell sorting (FACS) identified five distinct astrocyte subpopulations across the brain (i.e., "1-olfactory bulb," "2-cortex," "3-brainstem," "4-thalamus," and "5-cerebellum"). While these diverse subpopulations were shown to demonstrate different developmental functions and synaptogenesis support, they also separately correlated with different GBM subtypes at the molecular and cellular levels, thus providing new insights for understanding GBM progression dynamics and describing new potential GBM subtypes markers (John Lin et al., 2017) . Thus, the "classical" GBM subtype seemed to correlate with the expression profiles of populations 1-4, the "neural" GBM subtype with populations 1-3, and the "mesenchymal" GBM subtype uniquely with population 2. In contrast, the expression profile of the "proneural" GBM subtype did not coincide with any of these populations (John Lin et al., 2017; Verhaak et al., 2010) .
| Influence of tumor associated astrocytes on glioblastoma cells proliferation
Astrocytes expressing sonic hedgehog (SHH) pathway components are highly concentrated in the perivascular niche of gliomas (Becher et al., 2008) . Clement, Sanchez, de Tribolet, Radovanovic, and Altaba (2007) ) show that deregulation of SHH-Gli signaling results in hyperproliferation of precursor cells and may initiate brain tumors. In accordance with its role during cell differentiation, the SHH-Gli signaling in astrocytes of the perivascular niche is likely to be involved in initiating gliomas (Komada, 2012) . Similarly, the deregulation of stromal cell-derived factor-1 (SDF1)/CXCR4 signaling in astrocytes is thought to induce aberrant astrocytes proliferation, which can initiate the formation of a GBM tumor (Bonavia et al., 2003) .
Regarding reactive astrocytes, they are known to secrete high levels of factors such as tumor necrosis factor-α (TNF-α), tumor growth factor-β (TGF-β), IL-6, and insulin growth factor-1 (IGF-1) in response to CNS injury. All these factors have been shown to significantly increase the in vitro proliferation of cancer cells such as brainmetastatic breast or lung cancer cells but also primary brain tumors such as GBM (Nagashima, Suzuki, Asai, & Fujimoto, 2002; Placone, Quinones-Hinojosa, & Searson, 2016; Seike et al., 2011) . In the same way, GDF-15, observed as overexpressed in reactive astrocytes, has been shown to increase GBM cells in vitro proliferation while GDF-15 depletion decreases in vivo tumor growth (Roth et al., 2010; Zamanian et al., 2012) . GDF-15, a divergent member of the TGF-β gene family, is also overexpressed in GBM patients and seems to correlate with shorter survival of patients (Shnaper et al., 2009) . Overall, those reports highly suggest that, upon GBM rising, surrounding astrocytes might overexpressed proliferation factors such as TGF-β and GDF-15 to support the specific aberrant proliferation rates of tumor cells.
In the same picture, ion channels and ion transporters, expressed at the membrane of both astrocytes and GBM cells might then form a bridge between the two cellular types, thus enhancing tumor progression and therapeutic resistance, as suggested by a recent review (Guan, Hasan, Maniar, Jia, & Sun, 2018) . Also, the GBM-derived extracellular vesicles (EVs) might significantly alter the intracellular signaling and cytokine profile of normal human astrocytes to push them towards a tumor supporting behavior (Oushy et al., 2018) . EVs are membrane-enclosed nanospheres secreted by all cell types that are essential players in intercellular communication as they carry proteins, lipids, and nucleic acids between cells (Yanez-Mo et al., 2015) . It appears that the exposure of normal astrocytes to GBM EVs generates a growth-stimulant medium loaded with growth factors (VEGF, fibroblast growth factor (FGF), human growth factor (HGF), and EGF), chemokines, and interleukins. Consequently, proliferation of GBM cells has been detected as enhanced when exposed to conditioned medium derived from astrocytes under the influence of tumor EVs (Oushy et al., 2018) .
| Migration and invasion
In the tumor surrounding microenvironment, GBM invasion mostly occurs along anatomic features such as blood vessels but also astrocytes extensions Nakada et al., 2007) . This way, in addition to the effects on tumor cell proliferation, TAAs might also directly impact on the migration and invasion of GBM cells (Le et al., 2003; Rath, Fair, Jamal, Camphausen, & Tofilon, 2013) . To invade the surrounding tissue, GBM tumors remodel the ECM through the activity of enzymes such as matrixmetalloproteases (MMPs) (Coquerel et al., 2009) . Accordingly, a recent study elegantly showed an increase of the migration capabilities of GBM patient-derived cell lines (GBM10, GBM43, and GBAM1) when co-culture with astrocytes in a collagen-hyaluronan 3D matrix (Herrera-Perez et al., 2018) . Le et al. (2003) also showed that large amounts of reactive astrocytes are found in proximity to the tumor cells to mediate the activation of MMP2 and favor GBM invasion. In the same study, astrocytes were shown to directly participate in the interaction of the urokinase plasminogen activator (uPA) with its activator uPAR in U251 GBM cells in vitro. This, in turn, enhances the activation of plasmin-a serine protease that cleaves and activates MMP2 (Le et al., 2003) . The report then suggests that TAAs in the perivascular niche promote the uPAR-plasmin cascade to increase MMPs activation in GBM cells, consequently favoring invasion (Figure 1) . In a similar way, reactive astrocytes have been observed to secrete IL-6, a protein able to enhance primary GBM cell invasion in vitro (Chen et al., 2016b; Li et al., 2010) . Indeed, GBM development, aggressiveness, and poor prognosis have been linked to the high expression of IL-6 (Jiang, Han, Cheng, Wang, & Wu, 2017; Tchirkov et al., 2007) . Thus, Jiang et al. (2017) ) recently observed that the expression of both IL-6 and IL-6-R was directly correlated to the highly aggressive mesenchymal GBM subtype and poor survival. In the same way, Li et al. (2010) ) showed that IL-6 promotes the in vitro invasion of U87 GBM cells by upregulating the expression and secretion of MMP2 and fascin-1, an actin-bundling protein involved in the formation of cellular protrusions enabling cell migration. A separate study also reported a significant increase in the in vitro invasiveness of CD133+ GSCs when co-cultured with astrocytes or treated with astrocytes conditioned medium (Rath et al., 2013) . Interestingly, those effects appeared to be exclusive to CD133+ GSCs as co-culture or astrocyte conditioned medium failed to stimulate CD133− cell invasion. Furthermore, the authors observed well-known mediators of tumor cell invasion as secreted by astrocytes, such as osteopontin, TGF-β1, IL-6, and IL-8, while
GSCs expression of tumor aggressiveness markers such as CD44, CCl2, or hyaluronan synthase 2 (Has2) appeared to increase when co-cultured with astrocytes (Rath et al., 2013) . Altogether, these results suggest that TAAs might support the progression of aggressive GBM stem cells.
Similar effects have been observed in response to glial-cell derived neurotrophic factor (GDNF). GDNF-GFRα1 has been implicated in the progression of different types of tumors, including GBM (Wiesenhofer, Weis, & Humpel, 2000) . Therefore, using a murine glioma cell line (GL261), Shabtay-Orbach, Amit, Binenbaum, Na'ara, and Gil (2015)) showed that astrocyte-derived GDNF enhances GBM migration potential in vitro and promotes tumor progression in vivo. These data suggest that astrocyte-derived GDNF may be acting as a chemoattractant to promote GBM cell migration. In addition, through the addition of specific inhibitors to astrocytes conditioned medium, authors could be able to demonstrate that the astrocytes-derived GDNF effect on GBM cell migra- Brain-metastatic cancer cells also exhibit an increased invasion potential in the presence of astrocytes in vitro. A study by Marchetti, Li, and Shen (2000) ) suggests that astrocyte-derived NGF promotes the production of the extracellular degrading enzyme heparanase which in turn promotes brain-metastatic specificity invasion of melanoma cells in vitro. Transwell assays using a chamber coated with HSPGs show that in the presence of astrocytes conditioned medium, the invasiveness of melanoma cells lines significantly increases (Marchetti et al., 2000) . TAAs might thus be critical mediators of tumor metastasis invasion through the brain.
| Tumor associated astrocytes support glioblastoma cells survival
During GBM development, tumor cells easily adapt to the hypoxic conditions arising in their surrounding microenvironment, thanks to the activation of the HIF-1 signaling and the concomitant help from stromal cells, especially endothelial cells during the neoangiogenesis process (Quail & Joyce, 2017; Vasudev & Reynolds, 2014) . Interestingly, TAAs might also be involved in this GBM cell adaption to hypoxia. Indeed, a recent study using an in vitro GBM cells/astrocytes co-culture model reports that the astrocytes secretion of chemokine C-C motif ligand 20 (CCL20) increases in response to hypoxia, leading to an overexpression of HIF-1α in GBM cells through the binding of the chemokine to its receptor C-C chemokine receptor type 6 (CCR6) and the subsequent activation of the NF-κB pathway. Consequently, under hypoxic conditions, the GBM cells' proangiogenic potential (VEGF-A secretion and endothelial tubes formation), proliferation, and 3D invasion increased in response to conditioned medium from astrocytes previously exposed to hypoxia (Jin et al., 2018) . The CCL20/CCR6 axis has recently been associated with poor outcomes of different cancers but also seems to be highly present in high-grade gliomas compared to low-grade gliomas (Ding et al., 2012; L. Wang et al., 2012) . In addition, in line with these in vitro results, in vivo data showed a direct correlation between CCR6 expression and tumor development (Figure 2) . Overall, this new study underlines the direct implication of TAAs in GBM cells reaction to hypoxia but also suggests a more indirect involvement in the onset of the neoangiogenesis process during tumor growth (Jin et al., 2018) .
TAAs also facilitate GBM progression through promoting apoptosis evasion. Indeed, Oliveira et al. (2017) ) lately reported an increase of glioma cell viability in response to treatment with in vitro conditioned medium derived from glial cells that have been previously primed through co-culture with tumor cells. Compared to control, proteins described as being upregulated in the conditioned medium from primed glial cells are also known to be involved in processes such as cellular homeostasis, cell adhesion, inflammatory responses, and extracellular structure organization (Okolie et al., 2016) . In addition, proteins linked with tumor progression such as insulin-like growth factor-binding protein 2 (IBP-2) (Zhang et al., 2014) , MMP inhibitor 2 (TIMP2) (Lu, Jong, Rajasekaran, Cloughesy, & Mischel, 2004) , and SPARC-like protein 1 (Turtoi et al., 2012) were also found to be significantly upregulated (Oliveira et al., 2017) .
Moreover, the ECM of astrocytes with mutated p53 has recently been shown to facilitate apoptosis evasion in GBM cells (Biasoli et al., 2014) . Accordingly, p53 has also been found to be able to modulate the expression of tumor cells' secreted proteins, thus influencing the behavior of neighboring cells' (Khwaja et al., 2006) . In this way, it appears possible that p53 can be involved in modulating the ECM composition (Lu, Weaver, & Werb, 2012) . tumor cell resistance to apoptosis and migratory potential (Holohan, Van Schaeybroeck, Longley, & Johnston, 2013) . In the same study, GBM cells were found to be able to modulate the expression of p53 in astrocytes from the cerebral cortex of newborn mice (Biasoli et al., 2014) . Accordingly, this experiment elucidates the idea of an intercellular cross-talk where GBM cells trigger a decrease in the expression of p53 in local astrocytes that in turn prevents apoptosis of GBM cells.
In the same way, astrocyte-derived phosphoprotein enriched in astrocytes of 15 kDa (PEA-15) has been shown to increase the survival of GBM cells in vitro (Eckert et al., 2008) . PEA-15 is a multifunctional protein involved in glucose metabolism and regulating apoptosis (Fiory, Formisano, Perruolo, & Beguinot, 2009) . PEA-15 is overexpressed in diffuse/anaplastic astrocytomas and GBM compared to normal brain tissues, more specifically in astrocytes surrounding GBM tumors (Formstecher et al., 2001; Watanabe et al., 2010) . Eckert et al. demonstrated that PEA-15 protects GBM cells from glucose deprivation-induced apoptosis (Sulzmaier, Opoku-Ansah, & Ramos, 2012) . In addition, GBM cell lines overexpressing PEA-15 show PEA-15-dependent protection from low glucose-mediated cell death (Caro-Maldonado et al., 2010) . Consequently, suppressing the PEA-15 signaling reversed these protective effects (Eckert et al., 2008) . According to this, it is likely that a PEA-15-dependant mechanism might be involved in the astrocytes' support to GBM cells survival.
GBM cell-derived EVs have also been found to modulate surrounding astrocytes signaling, thereby promoting evasion of apoptosis in GBM cells (Oushy et al., 2018) . Indeed, Oushy et al. showed that the phosphorylation of BAD-a pro-apoptotic member of the Bcl-2 family that becomes inactive when phosphorylated-is observed in astrocytes grown in the presence of GBM cells-derived EVs. Similarly, other key oncogenic mediators such as ERK, AKT, and STATs (Steelman et al., 2004; Steelman et al., 2008) are also found increasingly phosphorylated in GBM EV-stimulated astrocytes. Overall, these studies suggest that a tight GBM/astrocytes cross-talk in the tumor microenvironment is important to limit tumor cells apoptosis, thus promoting aggressiveness (Oushy et al., 2018) . Having an in-depth understanding of the related underlying mechanisms may be important for the development of new innovative GBM treatments.
| Chemoprotection
TAAs might also be implicated in the protection of GBM cells against currently used chemotherapies. A study undertaken by Chen et al. (2015) ) showed that in vitro co-culture with astrocytes significantly decreases chemotherapy-induced apoptosis of A172 GBM cells. However, this protection is dependent on direct contact between GBM cells and astrocytes as separating the two cell populations using a transwell membrane abolished any cytoprotective effects previously observed. In addition to this, dye transfer assays revealed that when in co-culture, functional gap junctions are formed between astrocytes and glioma cells. Consequently, anti-tumor cells effect is increased when combined with carbenoxolone, a potent gap junctions communication inhibitor (Chen et al., 2015) . In addition, another report described the decrease of the intracellular Ca 2+ burst associated with chemotherapy induced-cytotoxicity when melanoma cells are co-cultured with astrocytes. This effect is abolished in the presence of carbenoxolone . Similarly, breast and lung can- (Chen, Boire, et al., 2016a) . Thus, according to these reports, specific gap junctions between astrocytes and GBM cells can participate in tumor cells resistance to chemotherapeutic agents.
| Immunoprotection
As cancer cells rise, the immune system gets immediately activated so it can fight the developing tumor through the actions of natural killer cells and T lymphocytes (Martinez-Lostao, Anel, & Pardo, 2015) .
Unfortunately, tumor cells become easily resistant to this natural immune reaction. Currently, there is no direct evidence that astrocytes are involved in GBM cell immunoprotection. Yet, reactive astrocytes secrete factors such as tenascin-C, IL-10, and STAT-3, which have all been linked to mechanisms implicated in immunoprotection of GBM cells (Huang et al., 2010) . Similarly, IL-10, an immunomodulatory cytokine with anti-inflammatory properties, has also been shown to stimulate survival of GBM cells, notably via inhibition of the expression of proinflammatory mediators such as Class II MHC and IFN-γ in vitro (Iyer & Cheng, 2012; Qi et al., 2016) . Class II MHC is involved in the antigen-presenting ability of monocytes while IFN-γ has been shown to induce the synthesis of IL-6 to support the immune eradication of GBM cell lines in vitro (Hotfilder et al., 2000; Lee et al., 2017; Yin et al., 2017) . In addition, STAT-3-another factor found up- 
| Tumor associated astrocytes-derived EVs
EVs allow the communication between both neighboring and distant cells (Tkach & Thery, 2016) . The composition of astrocyte-derived EVs is heterogeneous and has been involved in both physiological and pathological functions (Fruhbeis, Frohlich, Kuo, & Kramer-Albers, 2013 ). Yet, some of the content of astrocyte-derived EVs and their roles have been described; Hsp/c70 is linked to neuroprotection (Taylor, Robinson, Gifondorwa, Tytell, & Milligan, 2007) ; FGF-2, VEGF, endostatin, and PEDF are involved in modulating angiogenesis (Hajrasouliha et al., 2013; Proia et al., 2008) , while MMPs mediate ECM remodeling (Sbai et al., 2010) . According to this, even though this research is still in its infancy, an EVs-dependent influence of TAAs in GBM tumor supporting processes such as neo-angiogenesis and immune-modulation appears possible. Therefore, through in vitro co-culture methods, it has been reported that EVs from astrocytes might induce a decrease of the PTEN expression in breast cancer and melanoma metastatic cells in the brain microenvironment, thus enhancing tumor cell proliferation and resistance to apoptosis. Zhang et al. showed that exosomal-associated miRNAs are involved in this regulation (Zhang et al., 2015) .
| SIGNIFICANCE FOR FURTHER DIAGNOSIS, PROGNOSIS, AND THERAPEUTIC APPLICATIONS
As current therapeutic strategies (chemotherapies and targeted therapies such as anti-angiogenic treatments) are yet to be fully effective, TAAs appear to be new potential targets and/or source of biomarkers for GBM treatment. Both local (i.e., gap junctions) and distant (i.e., cytokines and EVs) roles of TAAs should be exploited. Based on this article, TAAS-produced IL-6 appears to be at the crossroads of multiple TAAs' effects on GBM development, including promoting proliferation and invasion but also modulating immune response to tumor progression (Chen, Xia, et al., 2016b; Jiang et al., 2017; Lee et al., 2017; Seike et al., 2011; Yin et al., 2017; Zamanian et al., 2012) .
This key cytokine might thus be considered as a target for new therapies but also as a specific biomarker since its expression has been observed as mostly associated with mesenchymal GBM (Jiang et al., 2017) . Nevertheless, most of the work that has been done on TAAs-IL-6 was in vitro, suggesting that further in vivo studies will be needed to strengthen its clinical relevance. For the same reasons, STAT-3 and GDNF, respectively implicated in TAAs' effect on immune reaction modulation and tumor migration, should also be considered for future strategies, especially since in vivo studies have already validated some of their crucial roles (Priego et al., 2018) . In addition, considering that EVs can travel long distances and consequently be found in patients' peripheral blood and urine, further extensive study of the TAAsderived EVs might also provide with new highly valuable biomarkers (Wendler et al., 2016; Zhang et al., 2015) . In the same way, evidences 
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